Silverarc Capital Management’s Cytokinetics CYTK Stock Holding History

Silverarc Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-71,203	Closed	-$4.69M	–	81
2026 Q1	$4.69M	Buy	+71,203	New	+$4.53M	0.48%	44
2025 Q4	–	Sell	-211,000	Closed	-$11.6M	–	79
2025 Q3	$11.6M	Buy	+211,000	New	+$8.69M	1.56%	20
2024 Q2	–	Sell	-50,000	Closed	-$3.51M	–	76
2024 Q1	$3.51M	Buy	+50,000	New	+$3.87M	0.97%	32
2023 Q1	–	Sell	-17,500	Closed	-$802K	–	86
2022 Q4	$802K	Buy	+17,500	New	+$753K	0.23%	73
2022 Q1	–	Sell	-58,190	Closed	-$2.65M	–	74
2021 Q4	$2.65M	Buy	58,190 +8,881	+18%	+$343K	1.07%	31
2021 Q3	$1.76M	Buy	+49,309	New	+$1.45M	1%	36

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silverarc Capital Management's CYTK Position: Q2 2026 in Review

Silverarc Capital Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 71,203 shares — an estimated $4.69M sold.

Silverarc Capital Management first reported a position in CYTK in Q3 2021 and held it in 6 quarters. The position peaked at $11.6M in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Silverarc Capital Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
Silverarc Capital Management sold 71,203 Cytokinetics shares in Q2 2026, an estimated $4.69M.
Silverarc Capital Management first reported a position in Cytokinetics in Q3 2021 and held it in 6 quarters.
Silverarc Capital Management's Cytokinetics position peaked at $11.6M in Q3 2025.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.